/

SGMOQ

Sangamo Therapeutics, Inc.Closed

0.1400−0.01 −6.67%USD

OTC Markets OTCPK · as of Oct 13, 16:00 ET · 15m delay

Open

0.1500

Prev close

0.1500

Day range

0.14000.1500

52-week range

0.03000.7200

Volume

476.30K0.18×

Mkt cap

58.00M

P/E ttm

—

Fwd P/E

-1.40

EPS ttm

-0.3500

Div yield

0.00%

Earnings

—

From 52w high

−80.56%

Price Chart

Yahoo Finance · delayed

SGMOQOct 13, 2026O 0.1500H 0.1500L 0.1400C 0.1400−0.0100 (−6.67%)Vol 818.40K

SMA 500.1476
SMA 2000.2307

1Y change −79.41% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

SGMOQ Sangamo Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: 0.00%
1 month: −6.67%
3 months: +75.00%
6 months: −46.15%
Year to date: −66.67%
1 year: −79.41%

Valuation & ownership

Market cap: 58.00M
Enterprise value: 49.79M
P/E (ttm): —
Forward P/E: -1.40
PEG ratio: —
Price / book: —
Price / sales (ttm): 1.68
EV / EBITDA: -0.47
EPS (ttm): -0.3500
EPS (forward): -0.1000
Beta (5y monthly): 1.57
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 414.29M
Float: 410.43M
Short % of float: 9.13%
Short ratio (days): 2.63
Held by insiders: 0.93%
Held by institutions: 9.58%
Avg volume (3m): 2.59M
50-day average: 0.1466
200-day average: 0.2323
52-week change: −79.41%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 45.2
vs 50-day SMA: −5.15%
vs 200-day SMA: −39.32%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 8.88%
Realised vol (20d, ann.): 66.2%
From 52-week high: −80.56%
From 52-week low: +366.67%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 34.56M
Revenue growth (yoy): −77.60%
Earnings growth (yoy): —
Gross margin: -227.67%
Operating margin: -2215.39%
Profit margin: 0.00%

DES

About Sangamo Therapeutics, Inc.

Yahoo Finance profile

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; giroctocogene fitelparvovec, a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male with moderately severe or severe hemophilia A. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc. ALS and Frontotemporal Lobar Degeneration; Takeda Huntington's Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California. On June 23, 2026, Sangamo Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Sector: Healthcare
Industry: Biotechnology
Employees: 142
Headquarters: Richmond, CA, United States

SEAS

Seasonality · SGMOQ

2007–2026 · monthly returns

Strongest month Feb +10.19%Weakest month Mar −6.94%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	28.6	-20.4	-41.9	-52.0	83.3	-77.3	40.0	128.6	-6.2	-6.7			−66.7%
2025	20.6	-17.1	-35.3	16.7	-39.0	14.9	0.0	-3.7	28.8	-10.4	-23.3	-8.7	−58.8%
2024	-14.8	152.2	-42.2	-23.9	9.8	-35.7	116.7	9.0	2.4	95.4	32.9	-54.9	+88.9%
2023	11.1	-12.6	-42.3	-16.5	-23.8	16.1	1.5	-26.5	-38.1	5.0	-31.7	25.6	−82.8%
2022	-19.6	-3.0	-0.7	-28.6	-12.0	13.4	3.6	25.9	-9.3	-10.4	-16.6	-14.2	−58.1%
2021	-12.5	-15.9	9.1	-6.0	-8.5	11.0	-20.0	3.4	-9.1	-9.9	2.1	-9.5	−52.0%
2020	-12.4	16.4	-25.3	27.9	37.3	-19.9	20.9	1.9	-14.4	9.4	-3.4	56.3	+86.5%
2019	1.8	-22.9	5.9	22.5	-25.1	23.1	11.5	-9.2	-17.0	0.0	19.3	-22.5	−27.1%
2018	27.1	14.9	-20.7	-16.8	4.1	-13.7	-3.9	33.7	-7.1	-25.3	-2.4	-7.2	−30.0%
2017	14.8	30.0	14.3	-7.7	41.7	29.4	-2.3	55.2	12.4	-17.3	30.6	1.2	+437.7%
2016	-33.7	-13.4	15.5	4.1	9.5	-16.1	9.3	-32.2	7.9	-23.3	-9.9	-4.7	−66.6%
2015	-15.9	31.5	-6.8	-21.1	-1.0	-9.5	-17.5	-17.4	-25.4	25.0	17.4	10.3	−40.0%
2014	39.2	-5.9	-0.7	-23.5	-5.1	16.2	-22.2	20.4	-24.5	12.5	-0.5	25.9	+9.5%
2013	59.2	6.5	-6.2	6.5	-21.4	-2.4	24.8	1.2	6.3	-10.8	30.4	13.8	+131.1%
2012	21.5	52.8	-7.0	-5.1	-4.5	24.3	-4.7	2.1	13.2	-8.6	3.1	4.9	+111.6%
2011	15.4	8.0	0.7	-13.8	-1.1	-17.0	-8.0	-0.2	-19.6	-23.7	-8.7	-6.3	−57.2%
2010	-7.1	-8.9	8.2	13.7	-26.1	-18.5	1.6	-21.2	15.5	8.7	24.9	42.5	+12.2%
2009	19.3	-14.0	18.5	0.5	-6.6	24.4	15.4	23.0	17.1	-35.2	1.7	9.4	+70.1%
2008	-12.1	2.2	-13.2	25.5	-13.1	-10.2	10.1	-8.8	-22.9	1.4	-68.5	41.5	−73.3%
2007	15.2	-7.1	-3.7	9.3	-1.9	11.4	7.3	26.2	28.4	34.6	-19.1	-15.3	+97.3%

INSD

Insider Activity · SGMOQ

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Apr 21, 2026	Davis Gregory DOfficer	Sale at price 0.25 per share.	69.8K	$17.69K
Apr 20, 2026	Dubois-Stringfellow NathalieOfficer	Sale at price 0.26 per share.	345.9K	$89.18K
Jun 11, 2025	Parker H StewartDirector	Stock Award(Grant) at price 0.00 per share.	25K	—
Jun 11, 2025	Markels JohnDirector	Stock Award(Grant) at price 0.00 per share.	25K	—
Jun 11, 2025	Horn Margaret ADirector	Stock Award(Grant) at price 0.00 per share.	25K	—
Jun 11, 2025	Meyers James RobertDirector	Stock Award(Grant) at price 0.00 per share.	25K	—
Jun 11, 2025	Carey Robert F.Director	Stock Award(Grant) at price 0.00 per share.	25K	—
Jun 11, 2025	Hillan Kenneth J.Director	Stock Award(Grant) at price 0.00 per share.	25K	—
Jun 11, 2025	Smith Karen Lesley M.D. Ph.D.Director	Stock Award(Grant) at price 0.00 per share.	25K	—
Jun 11, 2025	Beers CourtneyDirector	Stock Award(Grant) at price 0.00 per share.	25K	—
Feb 24, 2025	Macrae SandyChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	375K	—
Feb 24, 2025	Duraibabu PrathyushaChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	120K	—
Feb 24, 2025	Willoughby Scott BGeneral Counsel	Stock Award(Grant) at price 0.00 per share.	120K	—
Feb 24, 2025	Dubois-Stringfellow NathalieOfficer	Stock Award(Grant) at price 0.00 per share.	120K	—
Feb 24, 2025	Davis Gregory DOfficer	Stock Award(Grant) at price 0.00 per share.	49.7K	—

SGMOQ

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

SGMOQ

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Sangamo Therapeutics, Inc.

Seasonality · SGMOQ

Insider Activity · SGMOQ

Congress Trades · SGMOQ

Investors Holding SGMOQ

Investors Holding SGMOQ

Congress Trades · SGMOQ

Insider Activity · SGMOQ

Seasonality · SGMOQ

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Sangamo Therapeutics, Inc.

Earnings & Dividends

News